Validation of the Meet-URO score in metastatic clear cell renal cell carcinoma patients receiving second or third-line tyrosine kinase inhibitors-immune checkpoint inhibitors combination therapy

J Transl Med. 2024 Mar 3;22(1):232. doi: 10.1186/s12967-024-05014-z.

Authors

Sike He^#¹, Haoyang Liu^#¹, Junru Chen², Hao Zeng³

Affiliations

¹ Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, China.
² Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, China. jrchen@scu.edu.cn.
³ Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, China. kucaizeng@163.com.

^# Contributed equally.

No abstract available

Publication types

Letter

MeSH terms

Carcinoma, Renal Cell* / drug therapy
Humans
Immune Checkpoint Inhibitors
Tyrosine Kinase Inhibitors

Substances

Immune Checkpoint Inhibitors
Tyrosine Kinase Inhibitors

Supplementary concepts

Clear-cell metastatic renal cell carcinoma